Doro Shin
Content Marketing Director
Doro Shin heads the content marketing strategy and development for Pharma Intelligence, which provides insight on key trends in the pharma industry.
Her key achievements include managing, and producing, thought leadership, showcasing the individual and synergistic strengths of Pharma Intelligence analysts and services while overseeing content marketing strategy.
She joined Citeline, part of Informa, in 2007 as a Trialtrove analyst, and was responsible for the editorial content of Trialtrove for infectious diseases and genitourinary conditions, specializing in HIV and HCV. After regularly contributing to Citeline’s Thought Leadership, Doro began managing the program in 2015.
Before Informa, she spent 3 years at the University of California, San Francisco’s Women’s Global Health Imperative and managed Phase III HIV prevention clinical trials based in Zimbabwe. She has an MPH specializing in infectious diseases from UC Berkeley, and a BA in English Literature from the University of Pennsylvania.
Latest From Doro Shin
Pharma Intelligence Congratulates The CARE Awards Winners
The fourth annual CARE Awards returned to Boston, Massachusetts, 2 May to once again recognize and commend key achievements across the spectrum of drug development that took place in 2018.
R&D Successes Celebrated At 2018 CARE Awards
Informa Pharma Intelligence pays tribute to the people driving the advances in drug development and their commitments to advancing human health with the third annual CARE Awards.
R&D Successes Celebrated At 2018 CARE Awards
Informa Pharma Intelligence pays tribute to the people driving the advances in drug development and their commitments to advancing human health with the third annual CARE Awards.
A Status Check Of The Alzheimer’s Trial Landscape
Despite high-profile failures, including the recent disappointing results for Axovant Science’s Phase III MINDSET study, the trial landscape for Alzheimer’s disease remains busy.
Global Guidelines
A sampling of global guidelines on the use of genomic biomarkers in drug development.
One Size No Longer Fits All: The Personalized Medicine Trial Landscape
Success rates are higher for clinical trials that incorporate selective pharmacogenomics and pharmacogenetics (PGX) biomarkers, according to data from Informa's Trialtrove. Given the challenges of designing and administering trials to secure regulatory approval in areas of unmet medical need, the data provide some basis for optimism in realizing the promise of targeted, personalized therapies that improve health outcomes for individual patients.